Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

3D Medicines Office Locations

3D Medicines has an office in
Show all (1)

3D Medicines Financials and Metrics

Summary Metrics

Founding Date

2010

3D Medicines total Funding

$281 m

3D Medicines latest funding size

$140 m

Time since last funding

a year ago

3D Medicines investors

3D Medicines's latest funding round in October 2020 was reported to be $140 m. In total, 3D Medicines has raised $281 m
Show all financial metrics

3D Medicines Cybersecurity Score

Cybersecurity ratingPremium dataset

D

68/100

SecurityScorecard logo

3D Medicines Online and Social Media Presence

Embed Graph

3D Medicines News and Updates

Aravive Achieves Second Development Milestone from 3D Medicines

Milestone is Based on Approval of 3D Medicines’ IND in China to Participate in Aravive’s AVB-500 (3D-299) Phase 3 Clinical Trial for Platinum Resistant Ovarian Cancer Milestone is Based on Approval of 3D Medicines’ IND in China to Participate in Aravive’s AVB-500 (3D-299) Phase 3 Clinical Trial fo…

TRACON Pharmaceuticals Announces Acceptance of the Envafolimab (KN035) NDA by the NMPA in China that was Submitted by its Corporate Partners Alphamab Oncology and 3D Medicines

NDA was Submitted in November in the Indication of MSI-H/dMMR Cancer, Including Colorectal and Gastric Cancer NDA was Submitted in November in the Indication of MSI-H/dMMR Cancer, Including Colorectal and Gastric Cancer

SELLAS Life Sciences and 3D Medicines Announce Exclusive License Agreement for Development and Commercialization of Galinpepimut-S (GPS) and GPS+ in Greater China

- SELLAS to Potentially Receive Up To $202 Million, Inclusive of $7.5 Million Upfront License Fee and $8 Million Near-term Milestones, plus Tiered Royalties -

TRACON Pharmaceuticals Announces Submission for Approval of Envafolimab (KN035) with the NMPA in China by its Corporate Partners Alphamab Oncology and 3D Medicines

Submission for Approval Filed in Indication of MSI-H/dMMR Cancer, Including Colorectal and Gastric Cancer Submission for Approval Filed in Indication of MSI-H/dMMR Cancer, Including Colorectal and Gastric Cancer

Aravive and 3D Medicines Announce Strategic Collaboration to Develop and Commercialize AVB-500 in Greater China

Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, and 3D Medicines Inc., a China-based biopharmaceutical company developing next-generation immuno-oncology drugs, today announced a collaboration and exclusive license agreement for the development…

3D Medicines Frequently Asked Questions

  • When was 3D Medicines founded?

    3D Medicines was founded in 2010.

  • How many employees does 3D Medicines have?

    3D Medicines has 153 employees.

  • Who are 3D Medicines competitors?

    Competitors of 3D Medicines include VLVbio, HealthBanks and TOMA Biosciences.

  • Where are 3D Medicines offices?

    3D Medicines has an office in.

  • How many offices does 3D Medicines have?

    3D Medicines has 1 office.